• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Jan De Witte joins GHO Capital as Operating Partner

    2/11/25 4:30:00 AM ET
    $IART
    $RMD
    Medical/Dental Instruments
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $IART alert in real time by email

    Jan De Witte joins GHO Capital as Operating Partner

    Former CEO of Integra LifeSciences with significant strategic and operational experience to support GHO Capital's portfolio

    London, UK – 11 February 2025: Global Healthcare Opportunities, or GHO Capital Partners LLP ("GHO"), the European specialist investor in global healthcare, is pleased to announce the appointment of Jan De Witte as Operating Partner.

    Jan is an accomplished senior executive with extensive experience leading international growth and transformation for global technology and life sciences companies. Prior to joining GHO, he was Chief Executive Officer and member of the Board of Directors at Integra LifeSciences (("Integra", NASDAQ:IART), a global leader in regenerative tissue technologies, and neurosurgical and ENT solutions. At Integra Jan drove international expansion and operational excellence, and through strategic acquisitions and innovation added $1 billion to the total addressable market of the company's offerings.

    Prior to Integra, Jan served as CEO of Barco N.V. (EBR: BAR), directing the advanced visualisation technology company's digital transformation and global market expansion. He strengthened Barco's position in the healthcare, entertainment, and enterprise sectors through new product launches and operational improvements and global market expansions. Earlier in his career, he spent 18 years at GE Healthcare leading global teams in Digital Health, Services, Manufacturing, Quality and Supply Chain across the Americas, EMEA, and Asia. Jan's career started with foundational roles in Operations at Procter & Gamble and as Senior Consultant at McKinsey in Europe.

    Jan currently serves as a Director of ResMed Inc. (NYSE:RMD), a digital health and medical device leader. His board experience includes previous roles at Barco N.V. and international joint ventures. He holds an M.B.A. from Harvard Business School and Master's and Bachelor's degrees in electromechanical engineering with highest distinction from KU Leuven, Belgium.

    As Operating Partner, Jan will leverage his extensive leadership experience and global network to support and grow GHO's portfolio companies, as well as supporting with the firm's transatlantic deal origination.

    The Partners at GHO Capital commented: "Jan brings a wealth of healthcare industry expertise and a strong track record to our team as we look to implement our proven operational playbook and drive expansion and growth across our portfolio. The healthcare sector is experiencing significant innovation, supported by favourable market conditions, and Jan's experience will help us identify businesses with the most substantial growth potential. On behalf of the entire GHO team, we warmly welcome him and look forward to the positive impact he will make."

    Commenting on his new appointment, Jan De Witte, Operating Partner at GHO Capital, said: "My focus throughout my career has always been to support innovative healthcare companies as they grow and transform, whilst creating long-term investor value. I am excited to be joining GHO Capital, one of Europe's leading healthcare specialist private equity firms, who are committed to driving the highest standards across the healthcare sector. I look forward to working with the team and leveraging my expertise to support GHO's portfolio companies realise their full potential."

    -Ends-

    Further information:

    GHO Capital Partners LLP

    T +44 20 3700 7440

    E IR@ghocapital.com

    For Media Enquiries



    ICR Healthcare



    Amber Fennell, Angela Gray, Kris Lam











    Tel: +44 (0) 20 3709 5700



    ghocapital@icrhealthcare.com







    About GHO Capital

    Global Healthcare Opportunities, or GHO Capital Partners LLP, is a leading specialist healthcare investment advisor based in London. GHO Capital applies global capabilities and perspectives to unlock high growth healthcare opportunities, targeting Pan-European and transatlantic internationalisation to build market leading businesses of strategic global value. GHO Capital's proven investment track record reflects the unrivalled depth of our industry expertise and network. GHO Capital partners with strong management teams to generate long-term sustainable value, improving the efficiency of healthcare delivery to enable better, faster, more accessible healthcare. For further information, please visit www.ghocapital.com.



    Primary Logo

    Get the next $IART alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IART
    $RMD

    CompanyDatePrice TargetRatingAnalyst
    ResMed Inc.
    $RMD
    7/16/2026$234.00Outperform → Sector Perform
    RBC Capital Mkts
    ResMed Inc.
    $RMD
    7/13/2026$235.00Buy → Neutral
    Citigroup
    Integra LifeSciences Holdings Corporation
    $IART
    7/9/2026$19.00Market Perform
    BMO Capital Markets
    Integra LifeSciences Holdings Corporation
    $IART
    6/18/2026$25.00Hold → Buy
    Argus
    ResMed Inc.
    $RMD
    6/17/2026$230.00Overweight → Equal-Weight
    Morgan Stanley
    Integra LifeSciences Holdings Corporation
    $IART
    5/28/2026$16.00Sell → Neutral
    Citigroup
    ResMed Inc.
    $RMD
    4/15/2026Overweight
    Analyst
    Integra LifeSciences Holdings Corporation
    $IART
    4/15/2026Buy → Hold
    Argus
    More analyst ratings

    $IART
    $RMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Graves Jeffrey A bought $102,150 worth of shares (9,000 units at $11.35), increasing direct ownership by 28% to 41,086 units (SEC Form 4)

    4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)

    11/6/25 4:05:46 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    Essig Stuart bought $1,499,979 worth of shares (52,641 units at $28.49), increasing direct ownership by 12% to 487,922 units (SEC Form 4)

    4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)

    5/24/24 4:08:19 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    Hill Barbara B bought $995,816 worth of shares (36,350 units at $27.40) (SEC Form 4)

    4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)

    5/22/24 4:09:18 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    $IART
    $RMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Integra LifeSciences to Host Second Quarter 2026 Financial Results Conference Call on July 29, 2026

    PRINCETON, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will release second quarter 2026 financial results on Wednesday, July 29, 2026, prior to the market open. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company’s website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A webcast replay of the

    7/16/26 8:00:00 AM ET
    $IART
    Medical/Dental Instruments
    Health Care

    One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics

    Issued on behalf of Conexeu Sciences Inc.Conexeu Sciences Inc. (NASDAQ:CNXU) completed the 12-month P.R.O.O.F phase of its CXU preclinical program, which met its objectives across three pillars, facial, body, and mechanical performance, as it advances a single-formulation regenerative platform toward a predicate-based 510(k).USA News Group News CommentaryRENO, Nev. , July 9, 2026 /CNW/ -- In regenerative medicine, the durable advantage rarely comes from a single product; it comes from a platform that can be pointed at more than one problem. That is the framing behind a milestone from Conexeu Sciences Inc. (NASDAQ:CNXU), a preclinical-stage regenerative tissue company that has completed the P

    7/9/26 8:16:00 AM ET
    $EOLS
    $ABBV
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    Resmed Announces Agreement to Sell MatrixCare Business

    SAN DIEGO, July 07, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has entered into a definitive agreement to sell its MatrixCare business to Frazier Healthcare Partners, a private equity firm focused exclusively on health care. This move reflects Resmed’s 2030 strategy by focusing on high-growth, scalable opportunities in sleep health, breathing health and connected home-based healthcare. The divestiture also strengthens Resmed’s ability to reallocate capital and resources toward innovation, operational scale and long-term value creation across its connected, home-

    7/7/26 4:30:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    $IART
    $RMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ResMed downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded ResMed from Outperform to Sector Perform and set a new price target of $234.00

    7/16/26 8:47:08 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    ResMed downgraded by Citigroup with a new price target

    Citigroup downgraded ResMed from Buy to Neutral and set a new price target of $235.00

    7/13/26 9:02:22 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    BMO Capital Markets initiated coverage on Integra with a new price target

    BMO Capital Markets initiated coverage of Integra with a rating of Market Perform and set a new price target of $19.00

    7/9/26 9:28:53 AM ET
    $IART
    Medical/Dental Instruments
    Health Care

    $IART
    $RMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,090,771 worth of ResMed Common Stock (4,991 units at $218.55) as part of a pre-agreed trading plan (SEC Form 4)

    4 - RESMED INC (0000943819) (Issuer)

    7/9/26 7:40:12 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    SVP, Fin & Princ Acct Officer Mosebrook Jeffrey covered exercise/tax liability with 937 shares, decreasing direct ownership by 3% to 34,516 units (SEC Form 4)

    4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)

    7/6/26 4:43:40 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by EVP & President, SS Singh Harvinder

    4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)

    7/6/26 4:42:48 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    $IART
    $RMD
    SEC Filings

    View All

    ResMed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure

    8-K - RESMED INC (0000943819) (Filer)

    7/7/26 5:24:32 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    SEC Form 144 filed by ResMed Inc.

    144 - RESMED INC (0000943819) (Subject)

    7/7/26 10:07:44 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    SEC Form SD filed by Integra LifeSciences Holdings Corporation

    SD - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)

    5/29/26 4:42:09 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    $IART
    $RMD
    Leadership Updates

    Live Leadership Updates

    View All

    Integra LifeSciences Appoints Topaz Kirlew Chief Regulatory Officer

    PRINCETON, N.J., July 02, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a global leader in medical technology, today announced the appointment of Topaz Kirlew, DBA, MBA, as corporate vice president and chief regulatory officer. Kirlew will lead Integra's global regulatory affairs organization and oversee regulatory strategy, compliance, submissions, and transformation initiatives worldwide. Kirlew served as the interim regulatory leader for the company over the past several months, leading the global regulatory organization during an important period for the company. In her interim capacity, she provided oversight of regulatory compliance, managed activ

    7/2/26 8:30:00 AM ET
    $IART
    Medical/Dental Instruments
    Health Care

    Integra LifeSciences Announces Key Executive Appointments

    PRINCETON, N.J., June 23, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Corporation Holdings (NASDAQ:IART), a global leader in medical technology, today announced several leadership appointments within its commercial organization. These changes are designed to strengthen customer focus, accelerate execution, and support the company’s long-term growth strategy. Following the recent appointment of Mike McBreen as executive vice president and chief commercial officer, Robert T. Davis Jr. has been appointed executive vice president, Tissue Reconstruction and Distributed Technologies, where he will lead the wound reconstruction and soft tissue segments, as well as private label. Christopher Ki

    6/23/26 8:00:00 AM ET
    $IART
    Medical/Dental Instruments
    Health Care

    Resmed Chief Financial Officer Brett Sandercock to Retire; Aaron Bloomer Appointed as Successor

    SAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced that Brett Sandercock, Chief Financial Officer, plans to retire effective May 4, 2026. After conducting a comprehensive search, Aaron Bloomer has been appointed as his successor.  "After 27 years with Resmed, including 20 as CFO, Brett leaves an outstanding legacy of disciplined leadership and trusted partnership," said Mick Farrell, Chairman and CEO of Resmed. "Brett's leadership has helped guide Resmed through significant growth and transformation, while keeping a clear focus on long-term value creat

    4/30/26 4:10:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    $IART
    $RMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Integra LifeSciences Holdings Corporation

    SC 13G - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Subject)

    11/12/24 5:20:30 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Integra LifeSciences Holdings Corporation

    SC 13G/A - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Subject)

    11/12/24 12:54:20 PM ET
    $IART
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Integra LifeSciences Holdings Corporation

    SC 13G/A - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Subject)

    8/12/24 10:06:35 AM ET
    $IART
    Medical/Dental Instruments
    Health Care

    $IART
    $RMD
    Financials

    Live finance-specific insights

    View All

    Integra LifeSciences to Host Second Quarter 2026 Financial Results Conference Call on July 29, 2026

    PRINCETON, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will release second quarter 2026 financial results on Wednesday, July 29, 2026, prior to the market open. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company’s website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A webcast replay of the

    7/16/26 8:00:00 AM ET
    $IART
    Medical/Dental Instruments
    Health Care

    Resmed to Report Fourth Quarter Fiscal 2026 Earnings on August 6, 2026

    SAN DIEGO, June 30, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2026 on Thursday, August 6, 2026, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Location:         https://investor.resmed.comDate:               Thursday, August 6, 2026Time:               1:30 p.m. PT / 4:30 p.m. ETInternational:   London, Thursday, August 6, 2026, 9:30 p.m. BST                        Sydney, Friday

    6/30/26 4:30:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million

    Noctrix Health acquisition validates Angelini Ventures' strategy of investing in innovative healthcare companies addressing significant unmet medical needs and advancing connected health Rome, Italy, 3rd June 2026 – Angelini Ventures, the corporate venture firm of Angelini Industries focused on investing in companies developing innovative solutions in BioTech and HealthTech, announces that portfolio company Noctrix Health has been acquired by ResMed (NYSE:RMD), a global leader in sleep health and respiratory care, in a transaction valued at $340 million. The transaction further strengthens Angelini Ventures' mission to support the next generation of healthcare innovators, combining capit

    6/3/26 7:40:36 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care